Using controlled clinical trials to learn more about acute drug-induced liver injury

Hepatology ◽  
2008 ◽  
Vol 48 (5) ◽  
pp. 1680-1689 ◽  
Author(s):  
Paul B. Watkins ◽  
Paul J. Seligman ◽  
John S. Pears ◽  
Mark I. Avigan ◽  
John R. Senior
2021 ◽  
Vol 164 ◽  
pp. 105404
Author(s):  
Hao Niu ◽  
Judith Sanabria-Cabrera ◽  
Ismael Alvarez-Alvarez ◽  
Mercedes Robles-Diaz ◽  
Simona Stankevičiūtė ◽  
...  

2016 ◽  
Vol 30 (2) ◽  
pp. 95-101 ◽  
Author(s):  
Marzena Jurek ◽  
Masoud Mokhtarani ◽  
John M. Vierling ◽  
Dion F. Coakley ◽  
Jitendra Ganju ◽  
...  

Author(s):  
Morris Sherman

AbstractSince the early trials in viral hepatitis, more and more new drugs are being tested for use in various liver diseases. Since drug hepatotoxicity is a major cause of drugs under investigation not making it to market, the assessment of drug-induced liver injury in clinical trials of new drugs is crucial. This review will focus on the systems that are used to assess drug-induced liver injury in clinical trials and will discuss how some of these criteria are inappropriate or inaccurate in this function together with suggestions for improvement.


Drug Safety ◽  
2021 ◽  
Author(s):  
Juliana Hey-Hadavi ◽  
Daniel Seekins ◽  
Melissa Palmer ◽  
Denise Coffey ◽  
John Caminis ◽  
...  

2017 ◽  
Vol 4 (3) ◽  
Author(s):  
Erin S. Christensen ◽  
Rupali Jain ◽  
Alison C. Roxby

Abstract Drug-induced liver injury related to Triumeq (abacavir/lamivudine/dolutegravir) has not been reported in clinical trials. We report a case of hepatotoxicity related to Triumeq exposure in a human immunodeficiency virus–infected patient. Clinicians should remain aware of the risk for acute and late-onset hepatitis with these agents. Close monitoring is recommended.


Sign in / Sign up

Export Citation Format

Share Document